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Abstract
Background: Family planning (FP) is an essential health service and an important part of comprehensive HIV care.
However, there is limited information about the contraceptive needs of people living with HIV in sub-Saharan
Africa, which in turn has hampered efforts to expand and integrate FP services into existing HIV programs.
Methods: We performed a cross-sectional survey to determine FP prevalence and predictors among HIV-positive
women and men attending 18 public antiretroviral therapy (ART) clinics in Lusaka, Zambia. Trained peer counselors
administered the 10-question survey to those seeking care for five days at each of the target sites.
Results: From February to April 2014, we surveyed 7,046 HIV-infected patients receiving routine HIV services. Use of
modern contraception was reported by 69 % of female ART patients and 79 % of male ART patients. However,
highly effective contraceptive use and dual method use were low among women (38 and 25 %, respectively) and
men (19 and 14 %, respectively). HIV disclosure status (adjusted odds ratio (AOR) = 4.91, 95 % confidence interval
(CI) = 3.32–7.24 for women, AOR = 3.58, 95 % CI = 2.39–5.38 for men) and sexual activity in the last 6 months
(AOR = 5.80, 95 % CI = 4.51–7.47 for women, AOR = 6.24, 95 % CI = 3.51–11.08 for men) were associated with
modern contraceptive use in multivariable regression. Most respondents said they would access FP services if made
available within ART clinic.
Conclusions: While FP-ART integration may be a promising strategy for increasing FP service uptake, such services
must focus on assessing sexual activity and advocating for dual method use to increase effective contraceptive use
and prevent unintended pregnancies.
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Background
Worldwide, 220 million women have an unmet need for
contraception and 80 million unintended pregnancies
occur yearly [1, 2]. Women living with HIV appear to
have a higher rate of unintended pregnancy (51–90 %),
compared to broader global estimates (38 %) [3]. In
addition, the likelihood of pregnancy for HIV-infected
women is up to three times higher following initiation of
antiretroviral therapy (ART) [4–6]. Improvements in
quality of life and health status; renewed interest in sex
and changes in sexual behavior; and high cultural value
placed on parenthood likely influence this relationship
[7, 8]. However, HIV carries an increased risk of adverse
pregnancy outcomes as well, including miscarriage,
stillbirth, and mother-to-child HIV transmission [9–11].
Women with HIV are also more likely to die from
illness or disease progression during this critical
period [10, 12–16]. Helping people infected with HIV
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achieve their family planning (FP) intentions is an essen-
tial preventive health service and has been included as one
of the four prongs outlined by the United Nations (UN) to
reduce the burden of pediatric AIDS [17].
Integration of FP and HIV services is a cornerstone to
achieving global goals for maternal and child health
[17–20]. However, current FP-HIV service integration ef-
forts vary widely – from referral-based, co-located clinics
to all-inclusive “one provider-one session” approaches.
Due to the variety of contextual factors that may influence
program outcomes, there is no consensus model for how
best to integrate FP-HIV services. Given inherent chal-
lenges such as staff turnover, commodity shortages, and
inadequate health infrastructure, understanding the use of
contraception by ART patients is an initial step toward in-
tegration [21, 22]. To inform FP-HIV service integration
planning in Lusaka, Zambia, we sought to determine the
prevalence of modern contraception and dual method use
among ART patients and to identify associated factors.
Methods
We conducted a cross-sectional survey of FP use among
HIV-positive adults receiving HIV treatment in Lusaka,
Zambia. We recruited participants from all 18 public
sector, government supported ART clinics in the city.
Peer counselors from each clinic were trained to admin-
ister a short survey in the context of routine care. Be-
cause the survey was integrated into routine clinical
care, district health providers did not collect detailed in-
formation about rates or reasons for non-participation.
However, we believe non-response to be essentially ran-
dom because staff members were instructed to interview
everyone as part of their clinic visit. The survey com-
prised 10 questions designed to determine the patient’s
current pregnancy status (or, for male respondents, that
of the partner), HIV disclosure status, partner HIV sta-
tus, contraceptive use including method(s) used, reasons
for method non-use, and interest in accessing FP within
ART clinics. Patients were also asked if they had been
sexually active within the last 6 months and if they
wanted a child within the next year. Patients were
encouraged to answer questions in relation to their
primary partner. All responses were based on self-report;
no verification of pregnancy status or contraceptive use
was performed. We did not collect data about ART use,
though the majority of individuals enrolled in the program
have initiated HIV treatment [23]. We conducted the
survey over a five-day period in each clinic among con-
secutively presenting males age 15 or older and females
aged 15–49. Five-day sampling intervals were chosen for
each facility, out of consideration for operational issues
(e.g., staff workload, cost) and the large anticipated sample
size. Use of these program assessment data was approved
by the University of Zambia Biomedical Research Ethics
Committee (Lusaka, Zambia) and the University of North
Carolina at Chapel Hill Institutional Review Board
(Chapel Hill, NC, USA).
Descriptive statistics were used to determine prevalence
of contraceptive use, pregnancy status, future fertility
desires, HIV status disclosure, and sexual activity in the
last 6 months. Analyses were stratified according to
gender of the respondent. Condoms, oral contraceptive
pills, injectables, sub-dermal implant, intrauterine device,
and sterilization were considered modern contraception;
of those, all were considered highly effective except con-
doms. Dual method use refers to the use of condoms
(male or female) concurrently with another method of
contraception. These categorizations are based on estab-
lished definitions in the medical and public health litera-
ture [24]. Contraceptive use by male respondents also
included contraceptive use by their female partner, if
known. For each gender, backward-selection multivariable
logistic model was used to identify predictors independ-
ently associated with modern contraception and dual
method use. Variables were removed if the likelihood ratio
p-value was greater or equal to 0.2. Standard errors were
adjusted to account for intra-site correlation using the
‘cluster’ option in the logistic model. The analysis was
performed using Stata 14 MP (Statacorp, College
Station, Texas).
Results
From February to April 2014, 7605 patients from 18
public facilities completed the survey as part of routine
care. Of those, responses from 7046 (93 %) were in-
cluded in the analysis: 447 were excluded due to missing
gender and 112 (108 women, 4 men) were excluded
because they were outside the target age range. The
majority of patients included in the analysis were women
(69 %, n = 4872). The median age for women was
34 years (interquartile range, IQR 30–40) and for men
40 years (IQR 34–44). Of the 463 participants who were
pregnant or had a pregnant partner at the time of the
survey, 49 % reported that the pregnancy was un-
planned. Overall, 75 % of respondents reported they did
not want a child within the next year. Compared to
women, men were more likely to report sexual activity
in the last 6 months and to report an HIV-positive part-
ner, but less likely to report no partner. Approximately
5 % of women and men had not disclosed their HIV
status to their partner. More than 80 % of respondents
reported they would access FP services in ART clinic if
the services were available (Table 1).
Contraceptive use by women
Among the 3138 women using contraception, 99 %
reported using modern contraception. Most used only
male condoms (60 %). Injectable contraception (15 %)
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and oral contraceptive pills (11 %) were the next most
frequently reported methods used (Table 1). Overall,
38 % of women reported using a highly effective contra-
ceptive method. Among women who reported sexual
activity in the last six months but did not want a child
within the next year, 36 % reported using a highly effect-
ive method. The most common reason for not using
contraception was no partner (46 %) and desired preg-
nancy (18 %). One-quarter of women reported dual
method use for pregnancy and sexually transmitted in-
fection prevention. In multivariable analysis (Table 2),
women who were older, did not desire a child in the
next year, had disclosed their status to their partner, and
were sexually active in the last six months had higher
odds of using modern contraception. Highly effective
contraceptive use was more likely among women who
did not desire a child in the next year, had an HIV posi-
tive partner, had disclosed their status to their partner,
and were sexually active in the last six months (Table 3).
Similar trends were observed when we examined associ-
ations with dual method use (Table 4).
Contraceptive use by men
Of the 1608 men reporting current contraceptive use,
99 % reported using a modern method. Male condoms
were most frequently reported (79 %), followed by inject-
able contraception (8 %) and oral contraceptive pills use
(6 %) by the partner (Table 1). Overall, 18 % of men re-
ported use of a highly effective method of contraception.
Among men who reported sexual activity in the last six
months but did want a child in the next year, 19 %
reported using a highly effective method. Similar to
women, the most common reason for not using contra-
ception was no partner (31 %) followed by desired preg-
nancy (16 %). Dual method use was reported by 14 %. In
multivariable analysis (Table 2), men who did not want a
child in the next year, had disclosed their HIV status to
their partner, and were sexually active in the last six
months were more likely to use modern contraception.
Table 1 Characteristics of and reported contraceptive use
among HIV-positive respondents receiving antiretroviral therapy





n (%) n (%)
Age 4405 1994
Median (IQR) 34 (30–40) 40 (34–44)
15–24 322 (8) 36 (2)
25–34 1848 (42) 500 (25)
35–49 2225 (51) 1244 (62)
> 49 a 218 (11)
Client or partner currently pregnant 4686 1993
Yes 313 (7) 150 (8)
No, don’t know 4373 (93) 1843 (92)
Desire a child in the next year 4173 1839
Yes 1023 (25) 492 (27)
No, don’t know 3150 (75) 1347 (73)
HIV status disclosed to partner 4764 2129
Yes 3706 (78) 1858 (87)
No, don’t know 299 (6) 93 (4)
No partner 759 (16) 178 (8)
Partner’s HIV status 4819 2147
Negative 787 (16) 408 (19)
Positive 2851 (59) 1455 (68)
Unknown 346 (7) 92 (4)
No partner 835 (17) 192 (9)
Sexually active in previous 6 months 4602 2028
Yes 3526 (77) 1718 (85)
Using contraception 4542 2046
Yes 3138 (69) 1608 (79)
No 1404 (31) 438 (21)
Method of contraception used
Male condom 1867 (60) 1277 (79)
Injectable contraception 484 (15) 124 (8)
Oral contraceptive pill 342 (11) 96 (6)
Sub-dermal implant 252 (8) 59 (4)
Copper IUD 117 (4) 15 (1)
Female condom 23 (1) 23 (1)
Sterilization 11 (0.5) 1
Other 8 7
Dual method use by those using contraception 797 (25) 217 (14)
Reasons for not using family planningb
No partner 639 (46) 134 (31)
Desire pregnancy 250 (18) 71 (16)
Partner opposed 115 (8) 33 (8)
Fear of side effects 101 (7) 12 (3)
Table 1 Characteristics of and reported contraceptive use
among HIV-positive respondents receiving antiretroviral therapy
(ART) at 18 public sector clinics in Lusaka, Zambia (N = 7046)
(Continued)
Currently pregnant 112 (8) 50 (10)
Other 336 (23) 126 (25)
Would obtain family planning in ART clinic 4140 1941
Yes 3285 (79) 1637 (84)
No, don’t know 855 (21) 304 (16)
IQR interquartile range, IUD intrauterine device
aWomen aged > 49 years were excluded
bPercentages do not add to 100 as clients could select more than one reason
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The same variables predicted highly effective contra-
ceptive use and dual method use in multivariable
analysis (Tables 3 and 4).
Discussion
In this large cross-sectional survey in urban Zambia,
two-thirds of female and three-quarters of male ART
patients reported using modern contraception in their
primary relationship. However, dual method use (i.e.,
concomitant use of hormonal method with condoms)
and highly effective contraceptive use (i.e., a modern
method other than condoms) were low. Encouragingly,
most respondents reported they would access FP
services if made available within ART clinic. These find-
ings support calls to improve FP service provision and
prevent unintended pregnancies through integrated FP-
ART health services.
Compared to an earlier study performed in Lusaka
(2009–2010), more women reported hormonal contra-
ceptive use (34 versus 22 %) and dual method use (25
verses 18 %) in our current study [25]. The proportion
of HIV positive females using contraception was less
than that reported in rural Uganda (69 %) [4], Nigeria
(70 %) [26], and South Africa (86 %) [27], but higher
than reported in Malawi (46 %) [28], and Zimbabwe
(55 %) [29]. One recent study reported contraceptive
prevalence of 91 % among sexually active HIV-positive
men not desiring pregnancy in the next 6 months in
Kenya, Namibia, and Tanzania [30], which is higher than
was observed here. While the locations of these different
surveys varied (e.g., postpartum clinics, ART clinics),
these comparisons highlight the wide variation of
contraceptive uptake among people living with HIV in
sub-Saharan Africa.
A large proportion of women and men reported using
condoms alone for contraception. While condoms are
classified as a “modern” method, the rate of pregnancy
with typical use is much higher than with other non-
barrier contraceptive methods. However, the effective-
ness of condoms in preventing sexually transmitted
diseases is also important, particularly in settings
where HIV is highly prevalent. Concomitant use of
condoms alongside more reliable contraceptive
methods – i.e., dual method use – has been increas-
ingly emphasized, including by international agencies
such as the World Health Organization [24].
Over one-third of patients using hormonal contracep-
tion did not report concurrent condom use. Cytochrome
Table 2 Unadjusted and adjusted odds ratio (OR) of characteristics independently associated with current use of modern contraceptive
among HIV-positive respondents receiving antiretroviral therapy (ART) at 18 public sector clinic in Lusaka, Zambia (n = 4691)
Women Men
n = 3096 n = 1595
Predictors Unadjusted OR Adjusted ORa Unadjusted OR Adjusted ORa
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
Age (years)
15–24 ref ref ref ref
25–34 1.85 (1.51–2.27)* 1.48 (1.16, 1.90)* 9.42 (3.84–23.14)* 1.67 (0.40–6.96)
35–49 1.49 (1.18–1.86)* 1.57 (1.21–2.03)* 16.51 (6.99–38.98)* 2.70 (0.68–10.73)
> 49 13.77 (5.63–33.67)* 2.22 (0.60–8.29)
Desire a child in the next year
Yes ref ref ref ref
No/Don’t know 1.14 (0.87–1.49) 2.68 (2.10–3.43)* 1.62 (1.23–2.13)* 2.77 (1.76–4.37)*
HIV status disclosed to partner
No/don’t know/no partner ref ref ref ref
Yes 11.81 (8.54–16.34)* 4.91 (3.32–7.24)* 10.60 (7.39–15.20)* 3.58 (2.39–5.38)*
Partner’s HIV status
Negative/Don’t know/No partner ref ref ref
Positive 4.14 (3.33–5.15)* 1.24 (0.99–1.55) 2.71 (1.99–3.69)*
Sexually active in previous 6 months
No ref ref ref ref
Yes 9.57 (7.58–12.06)* 5.80 (4.51–7.47)* 7.35 (5.27–10.26)* 6.24 (3.51–11.08)*
Modern contraception includes condoms, oral contraceptive pills, injectables, sub-dermal implant, intrauterine device, and sterilization
*P-value < 0.01
aThe estimation method was backward-selection multivariable logistic model (cluster standard error) with removal probability being ≥ 0.2
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P450-inducing ART drugs may reduce hormonal contra-
ceptive effectiveness due to their effect on metabolism,
regardless of how the contraceptive is administered [31].
Multiple pharmacokinetic studies and case reports
implicate the non-nucleoside reverse transcriptase
inhibitor efavirenz in hormonal contraceptive method
failure [32–40]. A 12 % failure rate of the levonorgestrel
sub-dermal implant was recently reported among
women taking an efavirenz-based ART regimen [41]; this
is in stark contrast to the typically reported failure rates
of <1 % [42–44]. Since the World Health Organization
now recommends efavirenz as part of first-line ART,
providers should inquire about contraceptive method
use at each visit and reinforce dual method use, espe-
cially to those using hormonal methods.
In our survey, most ART patients would access FP
services if they were integrated within ART clinics. Male
condoms are readily available in most public sector HIV
care and treatment facilities, but patients who seek add-
itional and/or different methods must go to a separate
department for services. For smaller clinics, these
services may be located at a different health facility
altogether. While FP-ART integration can vary in scope,
implementation of integrated models have increased
modern contraceptive use and dual method use in Kenya
[45], South Africa [46], and Uganda [47]. New efforts in
Zambia have focused on making short-term methods
(oral contraceptive pills and injectables) available in
ART clinics, while strengthening referral networks for
long-acting reversible contraception (LARC) such as
sub-dermal implants and intrauterine devices. For ex-
ample, the Zambian Ministry of Health, in partnership
with the Society for Family Health, has posted dedicated
LARC providers in high-volume public FP clinics to
increase coverage of services [48]. In rural settings, such
an approach is now being extended via mobile FP clinics
to target underserved groups.
The desire for modern contraception among HIV-
infected individuals is important but can be difficult to
understand in field settings. Such data have obvious
benefits for programs, as they can directly inform oper-
ational and strategic planning. Understanding the desire
for modern contraception, particularly as it relates to
pregnancy intentions, may have important implications
for efforts to integrate FP and ART services. For
example, if a relatively high proportion of individuals
Table 3 Unadjusted and adjusted odds ratio (OR) of characteristics independently associated with current use of highly effective
contraception among HIV-positive respondents receiving antiretroviral therapy (ART) at 18 public sector clinic in Lusaka, Zambia (n= 4691)
Women Men
n = 1206 n = 295
Predictors Unadjusted OR Adjusted ORa Unadjusted OR Adjusted ORa
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
Age (years)
15–24 ref ref b
25–34 1.25 (0.99–1.57) 0.92 (0.63–1.35) 0.97 (0.72–1.31)
35–49c 0.78 (0.59–1.04) 0.57 (0.38–0.87) ref
> 49 0.48 (0.29–0.80)
Desire a child in the next year
Yes ref ref ref ref
No/Don’t know 1.60 (1.25–2.06)* 2.28 (1.74–2.99)* 2.20 (1.65–2.94)* 2.89 (1.99–4.19)*
HIV status disclosed to partner
No/don’t know/no partner ref ref ref ref
Yes 4.39 (3.32–5.80)* 2.32 (1.65–3.26)* 7.93 (2.87–21.95)* 7.32 (2.12–25.25)*
Partner’s HIV status
Negative/Don’t know/No partner ref ref ref
Positive 2.36 (2.05–2.71)* 1.44 (1.16–1.80)* 1.81 (1.33–2.46)
Sexually active in previous 6 months
No ref ref ref ref
Yes 3.19 (2.72–3.74)* 2.07 (1.62–2.65)* 2.14 (1.45–3.17)* 1.60 (0.95–2.70)
Highly effective modern contraception includes oral contraceptive pills, injectables, sub-dermal implant, intrauterine device, and sterilization
aThe estimation method was backward-selection multivariable logistic model (cluster standard error) with removal probability being ≥ 0.2
bNo man aged 15–24 years used highly effective modern method
cUsed as reference for men because 15–24 age category had no man using dual methods, making the age category highly unstable for referent
*P-value < 0.01
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desired pregnancy – as has been reported in other stud-
ies [49, 50] – there may be a “ceiling” on the uptake of
modern contraception, regardless of how efficient
service delivery may be. In addition, there is likely
heterogeneity across communities and over time. Unfor-
tunately, we did not collect the necessary information to
conduct this type of analysis. We recognize this as a
limitation of our study and advocate for its inclusion in
similar future work.
Our study had other limitations. First, we were unable
to investigate certain demographic, socioeconomic, and
medical predictors of contraceptive use, such as marital
status, education, number of living children, and dur-
ation of ART. Unfortunately, these data were not readily
available in our program assessment. Second, our exter-
nal validity may be limited, making it difficult to extend
our results to adolescents and young adults. Contracep-
tive use patterns may vary between the urban setting of
Lusaka and rural parts of Zambia. Third, while our
inclusion of men was novel – and provides insights from
key decision-makers in Zambian households – their
knowledge of contraception use by their female partner
may be incomplete, affecting the precision of our usage
estimates. Fourth, social desirability bias and recall bias
may have influenced patient responses to our survey
questions, leading to overestimates about key utilization
data and preferences [51]. Finally, we present results
from a programmatic assessment. While we have a
reasonably large sample size, it was not calculated based
on a priori assumptions about prevalence of FP use.
Because of the lack of data from non-respondents, it is
also possible that our sample was not fully representative
of the clinic population at large.
Conclusions
Our data suggest that ART patients use condoms for
contraception, especially if they are sexually active and
have disclosed their HIV status. While condoms are ef-
fective for preventing sexually transmitted diseases,
pregnancy is much more likely with typical condom use
compared to use of other non-barrier contraceptive
methods [24]. Thus, targeted interventions are needed
to ensure ART patients are aware of contraceptive effi-
cacy and the importance of dual method use, can easily
initiate the method that best meets their FP intentions,
and have the needed support to continue or switch
Table 4 Unadjusted and adjusted odds ratios (OR) of characteristics independently associated with dual method use among
HIV-positive respondents receiving antiretroviral therapy (ART) at 18 public sector clinic in Lusaka, Zambia (n = 1014)
Women Men
n = 797 n = 217
Predictors Unadjusted OR Adjusted ORa Unadjusted OR Adjusted ORa
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
Age (years)
15–24 ref b
25–34 1.45 (1.09–1.92)* 0.99 (0.70–1.40)
35–49c 0.98 (0.71–1.35) ref
> 49 0.54 (0.32–1.40)
Desire a child in the next year
Yes ref ref ref ref
No/Don’t know 1.59 (1.16–2.19)* 2.22 (1.66–2.98)* 2.16 (1.43–3.26)* 4.36 (1.30–4.62)*
HIV status disclosed to partner
No/don’t know/no partner ref ref ref ref
Yes 8.91 (4.81–16.49)* 4.35 (2.61–7.25)* 6.74 (2.46–18.46)* 2.33 (1.26–4.32)*
Partner’s HIV status
Negative/Don’t know/No partner ref ref ref
Positive 2.49 (2.09–2.97)* 1.34 (1.08–1.67)* 1.70 (1.21–2.40)*
Sexually active in previous 6 months
No 1 1 1 1
Yes 4.88 (3.21–7.42)* 2.78 (1.85–4.19)* 2.55 (1.40–4.65)* 6.24 (3.51–11.08)*
Dual method use refers to the use of condoms (male or female) concurrently with another method of contraception
aThe estimation method was backward-selection multivariable logistic model (cluster standard error) with removal probability being ≥ 0.2
bNo man aged 15–24 years used highly effective modern method
cUsed as reference for men because 15–24 age category had no man using dual methods, making the age category highly unstable for referent
*P-value < 0.01
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methods as fertility goals change. Collaborations
between reproductive health service providers and ART
providers are essential to ensure appropriate integration
of FP-HIV care to achieve these objectives. While
improvements are underway to increase FP access for
people living with HIV, additional research is needed to
identify effective integration methods that help reduce
unintended pregnancy.
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